Personalis (PSNL) shares surge 5.80% on new cancer genomics feature Real-Time Variant Tracker launch

Shares of Personalis (Nasdaq: PSNL) surged 5.8025% in pre-market trading on January 13, 2026, following the announcement of a new feature enhancing its cancer genomics offerings.

The company unveiled the Real-Time Variant Tracker, an add-on to its NeXT Personal molecular residual disease (MRD) test. This tool allows clinicians to monitor emerging resistance mutations and therapeutically actionable variants during cancer surveillance, including ESR1 mutations linked to treatment adjustments in breast cancer. The feature aims to provide oncologists with dynamic insights to refine patient care strategies.

Personalis positioned the launch as a milestone in personalized cancer management, with CEO Chris Hall emphasizing its role in advancing precision medicine. The Real-Time Variant Tracker is currently available through an Early Access Program for clinical leaders and biopharma partners, focusing on integration into research and targeted therapy development. The expansion of MRD testing capabilities aligns with the company’s broader mission to revolutionize cancer care through genomic innovation.

With this enhancement to its MRD test, Personalis is reinforcing its position in the precision oncology market, where real-time genomic insights are becoming increasingly vital. The company remains focused on expanding its clinical partnerships and leveraging data-driven innovations to improve patient outcomes. The Real-Time Variant Tracker could serve as a differentiator in the competitive landscape of cancer diagnostics and monitoring.